Gastrointestinal side effects were reported by 33.6 percent of patients given 20 mg of Acomplia ( rimnoabant ) per day versus 17.8 percent of those given a placebo according to the STRADIVARIUS study that involved 839 patients at 112 centers in North America, Europe, and Australia.
© Copyright 2003-2012 - Larry Hobbs - All Rights Reserved.